Curis Amends its Existing Collaboration with Aurigene for the Development and Commercialization of CA-170

 Curis Amends its Existing Collaboration with Aurigene for the Development and Commercialization of CA-170

Curis Amends its Existing Collaboration with Aurigene for the Development and Commercialization of CA-170

Shots:

  • Aurigene to fund and conduct P-IIb/III study assessing CA-170 + chemoradiation in ~240 patients with nsq. NSCLC and get exclusive rights to develop and commercialize CA-170 in Asia in addition to its existing rights in India and Russia, as per its previous agreement
  • Curis will retain the right to develop & commercialize CA-170 in the US, EU and ROW and will receive royalties on sales of the therapy in Asia
  • CA-170 (PO) is a dual inhibitor of VISTA and PDL1, being evaluated in P-IIa basket study, demonstrated efficacy in patients with nsq. NSCLC

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Just Dial

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post